Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

Analyzing the Growth Rate of the Major Depressive Disorder Market: What’s the Expected CAGR for the Next Decade?

The market for major depressive disorder has seen a consistent increase in size over recent time. It is projected to rise from $6.12 billion in 2024 to $6.28 billion in 2025, indicating a compound annual growth rate (CAGR) of 2.6%. This growth during the historic period can be contributed to the advancements in pharmaceuticals, increased mental health consciousness, psychological treatments, and public health programs.

In the coming years, we anticipate stable expansion in the market size for major depressive disorder. It’s projected to escalate to $7.13 billion by 2029, with a compound annual growth rate (CAGR) of 3.2%. Factors contributing to the growth throughout the forecast duration include advancements in precision medicine, telepsychiatry and teletherapy, innovative treatment methods, and the worldwide spread of mental health services. Significant trends expected within this period encompass early intervention, peer backing and digital communities, integrated approaches, as well as tactics for resilience and coping.

Which Macro and Microeconomic Factors Are Accelerating the Growth of the major depressive disorder Market?

The major depressive disorder market is predicted to expand due to an increase in substance abuse and alcoholism cases. Substance and alcohol misuse refer to harmful and excessive usage patterns that can result in undesirable physical, psychological, and social outcomes. Substance and alcohol misuse often coincide with major depressive disorder, exacerbating the risk of bodily and mental harm. For example, a study in July 2024 by the Substance Abuse and Mental Health Services Administration (a division of US Health and Human Services) revealed that 3.1% of people (about 8.9 million) misused opioids in 2023, and 21.8% of individuals aged 12 or above consumed marijuana, the most commonly used illegal drug. Furthermore, 9.4% of individuals aged 12 or more vaped nicotine in the previous month, a growth from 8.3% in 2022. Hence, the increasing instances of substance and alcohol misuse are contributing to the expansion of the major depressive disorder market.

Major Depressive Disorder Market Driver: Rise in Anxiety Cases Fuels Market Expansion

Request Your Free Major Depressive Disorder Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=13042&type=smp

What Are the Leading Organizations Impacting the Major Depressive Disorder Market’s Growth?

Major companies operating in the major depressive disorder market are:

• Pfizer Inc._x000D_

• Janssen Research And Development LLC_x000D_

• Merck and Co. Inc._x000D_

• Novartis AG_x000D_

• Sanofi-Aventis US LLC_x000D_

What Are the Most Prominent Trends Driving Change in the Major Depressive Disorder Market?

Key businesses in the major depressive disorder industry are concentrated on creating novel products and obtaining necessary approvals to establish a competitive edge. The number of approved drugs for treating major depressive disorder, such as VRAYLAR (cariprazine), is on the rise due to demand for safer and more effective therapies. For example, in December 2022, the US-based pharmaceutical corporation, AbbVie Inc., secured approval from the US federal agency, the Food and Drug Administration (FDA), for VRAYLAR (cariprazine) to serve as a supplementary therapy to antidepressants for adults with major depressive disorder (MDD). VRAYLAR is a groundbreaking atypical antipsychotic medication that regulates dopamine and serotonin levels in the brain and stands as the first atypical antipsychotic authorized as a supplementary treatment for major depressive disorder. Moreover, it comes in the form of a capsule and is ingested once daily.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/major-depressive-disorder-global-market-report

Which Key Segments of the Major Depressive Disorder Market Are Poised for Growth and Innovation?

The major depressive disorder market covered in this report is segmented –

1) By Treatment: Psychotherapy, Medications, Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), Other Treatments

2) By Diagnosis: Physical Examinations, Laboratory Tests, Psychiatric Evaluations, Diagnostic And Statistical Manual of Mental Disorders (DSM-5), Other Diagnosis

3) By End-User: Clinics, Hospitals, Other End-Users

Subsegments:

1) By Psychotherapy: Cognitive Behavioral Therapy (CBT), Interpersonal Therapy (IPT), Dialectical Behavior Therapy (DBT), Psychodynamic Therapy

2) By Medications: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), Atypical Antidepressants

3) Electroconvulsive Therapy (ECT): Unilateral ECT, Bilateral ECT, Modified ECT

4) Transcranial Magnetic Stimulation (TMS): Repetitive Transcranial Magnetic Stimulation (rTMS), Deep Transcranial Magnetic Stimulation (dTMS), Theta Burst Stimulation (TBS), Navigated Brain Stimulation (nTMS)

5) Other: Cognitive Behavioral Therapy (CBT), Psychodynamic Therapy, Interpersonal Therapy (IPT), Vagus Nerve Stimulation (VNS), Ketamine Therapy, Bright Light Therapy, Psychedelic-Assisted Therapy, Medication (Antidepressants)

What Regions Are Leading the Charge in the Major Depressive Disorder Market?

North America was the largest region in the major depressive disorder market in 2024. The regions covered in major depressive disorder market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

How Is the Major Depressive Disorder Market Categorized and Defined in the Industry?

Major depressive disorder refers to a mood disorder or depression that causes a persistent feeling of sadness and loss of interest, which can interfere with daily activities such as sleeping, eating, or working. It goes beyond normal fluctuations in mood and can significantly impact a person’s thoughts, feelings, behavior and physical well-being. The treatment for major depressive disorder involves several medical interventions that support the emotional well-being of an individual.

Browse Through More Similar Reports By The Business Research Company:

Residential Substance Abuse And Mental Health Facilities Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/residential-substance-abuse-and-mental-health-facilities-global-market-report

Mental Health Apps Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/mental-health-apps-global-market-report

Telepsychiatry Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/telepsychiatry-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: